Our analysis of the publicly available databases indicated that mutation JAK2 V617F was found in 6% of blasts from AML patients, and that expressions of FGFR1 and JAK3 were significantly higher in AML patients than in healthy people (Figure S1 and Figure 1). This evidence concerns the gene JAK3 and acute myeloid leukemia.